Integra LifeSciences Holdings
What analysts say:
- Buy, sell, or hold?: Analysts think investors should stand pat on Integra LifeSciences Holdings, with nine out of 14 analysts rating it hold. While analysts still rate the stock a hold, they are a little more optimistic about it compared to three months ago.
- Revenue forecasts: On average, analysts predict $202 million in revenue this quarter. That would represent a rise of 4.1% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.67 per share. Estimates range from $0.65 to $0.69.
What our community says:
CAPS All-Stars are solidly behind the stock, with 93.9% granting it an outperform rating. The community at large backs the All-Stars, with 92.8% assigning it a rating of outperform. Fools are impressed with Integra LifeSciences Holdings, though the message boards have been quiet lately, with only one post in the past 30 days. Integra LifeSciences Holdings has a bullish CAPS rating of five out of five stars that is about on par with the Fool community assessment.
Integra LifeSciences Holdings' income has fallen year over year by an average of 33% over the past five quarters. Revenue has now gone up for three straight quarters.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Integra LifeSciences Holdings now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Earnings estimates provided by Zacks.